{"nctId":"NCT01258049","briefTitle":"Superiority of ArTiMist Versus Quinine in Children With Severe Malaria","startDateStruct":{"date":"2010-12"},"conditions":["Plasmodium Falciparum Malaria"],"count":151,"armGroups":[{"label":"ArTiMist","type":"EXPERIMENTAL","interventionNames":["Drug: Artemether Sublingual Spray"]},{"label":"Quinine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Quinine"]}],"interventions":[{"name":"Artemether Sublingual Spray","otherNames":["ArTiMist"]},{"name":"Quinine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. The patient's legally acceptable representative has provided informed consent and the patient has assented (where relevant) to participation in the trial\n2. The patient is a child that weighs between 5.00 kg and 15.00 kg inclusive\n3. The patient has falciparum malaria as evidenced by thick or thin blood smears of ≥ 500 P Falciparum per mcl (patients with mixed infections may be included provided ≥ 500 P Falciparum per mcl)\n4. The patient has either:\n\n   * severe or complicated falciparum malaria as determined by the investigator based on the WHO criteria for severity, and/or\n   * uncomplicated falciparum malaria but is unable to tolerate oral medication as a result of gastrointestinal complications such as vomiting or diarrhoea.\n\nExclusion Criteria:\n\n1. The patient's legally acceptable representative does not provide informed consent for participation, or the child if capable, does not assent to participation in the trial.\n2. Ability to tolerate oral therapy\n3. Patient has received any antimalarial therapy within the 7 days prior to first study drug administration.\n4. Patient has evidence of significant co-infections (this does not include mixed Plasmodium infections).\n5. Patient has a contraindication, allergy or is otherwise intolerant to either artemether or quinine .","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Parasitological Success (MITT)","description":"Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Parasite Clearance Time (PCT) [MITT Population]","description":"Parasite clearance time (PCT). Time in hours from the initiation of therapy until the first of two successive parasite negative smears (zero parasite counts) are obtained","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.29","spread":"13.21"},{"groupId":"OG001","value":"68.30","spread":"98.04"}]}]}]},{"type":"SECONDARY","title":"PCT 90 [MITT Population]","description":"Time for parasite counts to fall by 90%","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.02","spread":"5.82"},{"groupId":"OG001","value":"27.93","spread":"18.03"}]}]}]},{"type":"SECONDARY","title":"PCT 50 [MITT Population]","description":"Time for parasite counts to fall by 50%","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.42","spread":"5.72"},{"groupId":"OG001","value":"18.58","spread":"9.19"}]}]}]},{"type":"SECONDARY","title":"PRR 24 [MITT Population]","description":"The percentage reduction in parasite counts 24 hours after first dose","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":"6.12"},{"groupId":"OG001","value":"44.5","spread":"114.27"}]}]}]},{"type":"SECONDARY","title":"PRR 12 [MITT Population]","description":"The percentage reduction in parasite counts 12 hours after first dose","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":"70.28"},{"groupId":"OG001","value":"-132.2","spread":"765.92"}]}]}]},{"type":"SECONDARY","title":"Fever Clearance Time (FCT)","description":"Time in hours from the initiation of therapy until the disappearance of fever (tympanic temperature \\< 38.0) that lasted at least 24 hours.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":"34.47"},{"groupId":"OG001","value":"41.6","spread":"22.73"}]}]}]},{"type":"SECONDARY","title":"Complete Cure Rate","description":"The complete resolution of clinical signs and symptoms, malaria-related laboratory abnormalities, and elimination of asexual parasites by Day 7, with no recurrence up to Day 28 (+/- 2 days), and the 48h parasite count to be \\< 25% of baseline with no clinical deterioration","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Treatment Failure","description":"Early treatment failure is indicated by one or more of the following:\n\n* Parasite count on Day 2 \\> Day 0, irrespective of temperature\n* Parasite count on Day 3 \\> 0 with tympanic temperature ≥ 38.0°C\n* Parasite count on Day 3 ≥ 25% of baseline\n* Administration of rescue antimalarial treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Late Clinical Failure","description":"* Signs of severe malaria on any day between Day 4 and Day 28 in the presence of parasitaemia, without previously meeting any of the criteria of early treatment failure\n* Presence of parasitaemia and tympanic temperature ≥ 38.0°C (or history of fever), on any day between Day 4 and Day 28, without previously meeting any of the criteria of early treatment failure","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Parasitological Success (PP)","description":"Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Late Parasitological Failure","description":"o Parasitaemia on any day from Day 7 to Day 28 and tympanic temperature ≤ 38.0°C","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Return to Full Consciousness","description":"Time in hours to return to full consciousness (Blantyre Coma Scale = 5), if level of consciousness is reduced (Blantyre Coma Scale \\<5) prior to dosing or within 24hours of first dosing.\n\nFor the Blantyre Coma Scale\n\nTotal - maximum 5, eye movement - maximum 1, best motor response - maximum 2, best verbal response - maximum 2","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":"9.58"},{"groupId":"OG001","value":"23.0","spread":"16.52"}]}]}]},{"type":"SECONDARY","title":"Time to Return to Normal Per os Status","description":"Time in hours to return to normal per os status. Normal per os was when the investigator considered the patient to be able to eat and drink normally.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":"12.89"},{"groupId":"OG001","value":"25.3","spread":"16.28"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, of Possible, Probably and Definite Causalities","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Deaths or Neurological Sequelae at Day 28","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":77},"commonTop":["Malaria","Anaemia","Pyrexia","Respiratory Tract Infection","Cough"]}}}